Merck resolves Vytorin case for $688m


Merck & Co has agreed to pay $688 million (£445 million) to settle claims that it failed to report clinical trial data relating to cholesterol brands Zocor (simvastatin) and Vytorin (ezetimibe, simvastatin).

The case against the company was brought by a group of disgruntled investors, who claim Merck unfairly withheld negative information about the brands for a year.

In March 2008, Merck and Schering-Plough – which later merged under the Merck banner – published results of a key Vytorin trial that showed the drug did not work as well as expected. In the immediate aftermath, the share prices for the two dropped sharply. But the investors claim that the two companies knew that the trial was a flop at least a year before that.

The company will now pay $215 million to resolve the case against Merck and $473 million to resolve the case against Schering-Plough. However, it made no admission of wrongdoing and says that both companies acted responsibly in relation to the trial.


Related Content

Business roundup

27 January 2009 Business

news image

Industry news, February 2009

Business roundup

28 April 2008 Business

news image

Industry news

Most Read

No-frills coats set a trend for designer viruses

26 August 2014 Research

news image

An artificial protein that self-assembles around and protects DNA could be ideal for gene therapy, nanomachines and synthetic...

History of King Richard III written in his teeth

18 August 2014 Research

news image

Chemical analysis of isotope signatures in monarch's remains provide insight into his life

Most Commented

The energy to fight injustice

23 July 2014 Comments

news image

Giving the world carbon-free energy means putting nuclear energy back on the agenda, says James Hansen

Next Mars rover will make oxygen from CO2

4 August 2014 News and Analysis

news image

Mars 2020 will set Nasa’s space exploration on a self-sufficiency course